London, 31 July 2015 -- Moody's Investors Service has today withdrawn the B1 corporate family rating (CFR) and B1-PD probability of default rating (PDR) of Rottapharm SpA ("Rottapharm"). The ratings were put on review for downgrade on 5 August 2014 following an announcement whereby Meda AB (unrated) said it had reached an agreement to acquire Rottapharm for an enterprise value of EUR2.275 billion.

Vollständigen Artikel bei Moodys lesen